Human papillomavirus (HPV): systemic treatment with Gene-Eden-VIR/Novirin safely and effectively clears virus

Abstract

PurposeThis paper reports the results of a clinical study that tested the effect of systemic treatment with the botanical product Gene-Eden-VIR/Novirin on the clearance rate (also called time to clearance) of the human papillomavirus (HPV). The study compared the clearance rate in treated and untreated individuals suffering from a symptomatic HPV infection. The data on the untreated individuals were obtained by reverse engineering of the Kaplan–Meier figures in five published papers.Materials and methodsThe study included 59 treated participants. All participants were suffering from a symptomatic HPV infection prior to the commencement of treatment. The treatment was one to four capsules of Gene-Eden-VIR/Novirin per day. The duration of treatment was 2–12 months. The study included five groups of external controls with diverse characteristics.ResultsThe mean time to clearance in Gene-Eden-VIR/Novirin-treated individuals was 5.1 months or 151.5 days (95% CI: 4.2–5.9 months or 95% CI: 125.7–177.3 days, respectively). The median time to clearance was 3.5 months. The mean time to clearance in the five untreated groups ranged from 6.9 to 20.0 months (P<0.0001 for the difference between treatment group and each untreated group). Also, 100% of the participants in the treatment group were HPV free at the end of 12 months vs 53%, 52%, 65%, 20%, and 77% in the untreated control groups. The treated participants reported no adverse experiences.ConclusionThis clinical study has two major contributions. First, it showed that systemic treatment with the natural Gene-Eden-VIR/Novirin decreased the time to HPV clearance, increased the percentage of HPV-free individuals, and caused no adverse experiences in individuals suffering from a symptomatic HPV infection. Since there are no other systemic treatments for symptomatic HPV infections, this study presents highly valuable information on the clinical effects of the first treatment in this category. Second, the study presents a new method for conducting clinical studies that addresses one of the major deficiencies associated with the practice of the randomized controlled trial method.

Nanomaterial Complexes Enriched With Natural Compounds Used in Cancer Therapies: A Perspective for Clinical Application

“…59 patients were treated for 551 days, proving that the treatment showed 100% patients were HPV free. The analysis of results did not show adverse experiences in symptomatic patients; in contrast, the results weren’t replicable in asthma patients; for these reasons more studies are necessary ( 35 ). Another Qr application is the control of metabolic diseases.…”

Comparison of Serum and Dietary Selenium Levels in Participants with a Positive History of Recurrent Herpes Lesions and Healthy Individuals

“…Selenium supplementation induces faster healing of viral lesions including HSV2 (herpes simplex virus 2) [27], human herpes virus 3 (HHV3) [28], cytomegalovirus [8], and oral human papillomavirus (HPV) [27,29]. In addition to viral load, reduction in different antiviral cytokine increments after selenium supplementation has also been reported.…”

Coronavirus disease 2019 (COVID-19): first indication of efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 infection

“…Its formula includes five ingredients: a 100 mg extract of quercetin, a 150 mg extract of green tea, a 50 mg extract of cinnamon, a 25 mg extract of licorice, and 100 μg of selenium. Clinical trials showed that Gene-Eden-VIR/Novirin is effective against several viruses, including the Human Papillomavirus (HPV) 3 , Herpes Simplex Virus 4 (HSV), Epstein-Barr virus (EBV), and human Cytomegalovirus (hCMV). In the next section, we review evidence on the effect of the Gene-Eden-VIR/Novirin five ingredients on betacoronaviruses, and specifically, the SARS-…”